Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 215

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 215
---
 Closing and pursuant to the terms of the Merger Agreement. As of September30, 2025, Aptorum’s directors and executive officers owned, in the aggregate, 10.28% of the outstanding shares of Aptorum’s Class A ordinary shares. These interests may have influenced the Aptorum Board in making their recommendation that you vote in favor of the approval of the Merger. The members of the Aptorum Board were aware of and considered these interests, among other matters, when they approved the Merger and recommended that Aptorum stockholders approve the proposals required to effect the Merger, as well as the other proposals contained herein. The Aptorum Board determined that the overall benefits expected to be received by Aptorum and its stockholders in the Merger outweighed any potential risk created by the conflicts stemming from these interests. In addition, the Aptorum Board determined that potentially disparate interests would be mitigated because (i) most of these disparate interests would exist with respect to a business combination by Aptorum with any other target business or businesses and (ii) these interests could be adequately disclosed to stockholders in this proxy statement/prospectus, and that stockholders could take them into consideration when deciding whether to vote in favor of the proposals set forth herein. Interests of DiamiR Directors, Officers and Affiliates in the Merger In considering the recommendation of the DiamiR Board with respect to approving the Merger, stockholders should be aware that DiamiR directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of DiamiR stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. From June 2020 through April 2023, Kira Sheinerman, one of the founders and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which role included reviewing therapeutic and diagnostic opportunities, and making industry and academia introductions for Aptorum. Kira Sheinerman currently hold 2,772shares of Aptorum and is a managing director at Wainwright, with which DiamiR has a financial advisory agreement pursuant to which Wainwright acts as exclusive financial advisor to DiamiR in connection with the Merger. Additionally, Dr. Sheinerman owns less than one percent (1%) of Aptorum’s Class A ordinary shares and will be appointed to the Combined Company’s board of directors. Dr. Mireskand